Legal & General Group PLC Sorrento Therapeutics, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.74 - $1.83 $18,740 - $46,344	25,325 Added 7.68%	355,278 $316,000
Q3 2022 Nov 14, 2022	SELL	$1.51 - $2.88 $24,202 - $46,160	-16,028 Reduced 4.63%	329,953 $518,000
Q2 2022 Aug 22, 2022	BUY	$1.24 - $2.33 $95,699 - $179,822	77,177 Added 28.71%	345,981 $696,000
Q1 2022 May 16, 2022	BUY	$2.0 - $4.9 $6,286 - $15,400	3,143 Added 1.18%	268,804 $627,000
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.23 $116,203 - $180,677	24,990 Added 10.38%	265,661 $1.24 Million
Q3 2021 Nov 15, 2021	BUY	$7.41 - $10.99 $1.29 Million - $1.91 Million	173,764 Added 259.71%	240,671 $1.84 Million
Q2 2021 Aug 12, 2021	BUY	$6.35 - $10.0 $41,554 - $65,440	6,544 Added 10.84%	66,907 $649,000
Q1 2021 May 17, 2021	SELL	$7.03 - $16.51 $13,792 - $32,392	-1,962 Reduced 3.15%	60,363 $500,000
Q4 2020 Feb 12, 2021	BUY	$5.76 - $11.95 $40,930 - $84,916	7,106 Added 12.87%	62,325 $425,000
Q3 2020 Nov 13, 2020	SELL	$6.17 - $18.82 $13,179 - $40,199	-2,136 Reduced 3.72%	55,219 $616,000
Q2 2020 Aug 14, 2020	BUY	$1.73 - $6.76 $62,337 - $243,583	36,033 Added 168.99%	57,355 $360,000
Q1 2020 May 14, 2020	SELL	$1.57 - $4.76 $7,980 - $24,195	-5,083 Reduced 19.25%	21,322 $39,000
Q4 2019 Feb 13, 2020	BUY	$1.45 - $4.17 $4,228 - $12,159	2,916 Added 12.41%	26,405 $89,000
Q1 2019 May 15, 2019	BUY	$1.86 - $5.94 $6,826 - $21,799	3,670 Added 18.52%	23,489 $111,000
Q4 2018 Feb 15, 2019	BUY	$2.01 - $4.24 $6,908 - $14,572	3,437 Added 20.98%	19,819 $47,000
Q3 2018 Nov 20, 2018	BUY	$4.22 - $7.5 $14,407 - $25,605	3,414 Added 26.33%	16,382 $72,000
Q2 2018 Aug 10, 2018	BUY	$4.75 - $8.0 $61,598 - $103,744	12,968 New	12,968 $93,000

Others Institutions Holding SRNE

# of Institutions

Shares Held

5.47M

Call Options Held

Put Options Held

View Full List

About Sorrento Therapeutics, Inc.

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

More about SRNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account